Thunder Bioscience

Thunder BioScience is a South Korean biotechnology company focused on the development of innovative RNA-based therapeutics, particularly small interfering RNA (siRNA). The company leverages its proprietary T-BLOC (Targeted Bio-Linker for Oligonucleotide Conjugation) platform to address the historical challenges of RNA delivery, such as stability and tissue-specific targeting. By utilizing advanced conjugation chemistry, Thunder BioScience aims to deliver therapeutic payloads directly to diseased cells while minimizing off-target effects. Their current pipeline is primarily centered on oncology, with lead programs targeting solid tumors in the pre-clinical stage. The company is positioned to advance these candidates toward clinical trials to provide new treatment options for patients with high unmet medical needs.